Participation in conferences in Chile and Los Angeles, USA connects the Singapore MedTech company with international clinicians and potential distribution partners.

Bioactivx presented its Singapore-developed Bioactiv® Matrix to international wound-care communities through its recent participation in the International Society for Burn Injuries (ISBI) Congress inChile and DFCon 2026 in Los Angeles.

The two conferences provided opportunities to share early clinical evidence, engage healthcare professionals and explore potential partnerships for the fully synthetic regenerative skin substitute.

First-in-Human Findings Presented at ISBI Congress

At the ISBI Congress, Dr Fong Hui Chai, Consultant Plastic Surgeon at Singapore General Hospital (SGH), presented results from the First-in-Human pilot study of Bioactiv® Matrix to an international audience of burns specialists.

The presentation marked an important opportunity to share the technology’s early clinical findings and support discussion with clinicians from different healthcare settings.

During the Congress, Bioactivx engaged surgeons, nurses and distributors from countries including the United States,China, India, Greece, Turkey, Colombia, Brazil, Panama, Argentina, Peru andChile.

Clinical discussions focused on the science behind Bioactiv® Matrix, its early clinical outcomes and practical considerations in wound care. Potential distribution partners also expressed interest in exploring opportunities to introduce the product to their respective markets.

Clinical Insights at DFCon 2026

Following the ISBI Congress, Bioactivx travelled to Los Angeles for DFCon 2026, organised by the American Limb Preservation Society.

The event broadened the company’s engagement with clinicians working in diabetic foot care and limb preservation, offering insights into unmet needs and priorities for future product development.

During the conference, the team met Dr David Armstrong, a leading clinician and researcher in diabetic foot care and limb preservation. Discussions covered Bioactiv® Matrix and its potential relevance to diabetic foot ulcers, with Dr Armstrong sharing perspectives on clinical needs and considerations for further development.

These exchanges will help inform Bioactivx’s assessment of potential future applications. The use of Bioactiv®Matrix in diabetic foot ulcers remains an area for further investigation and would require dedicated clinical evaluation and relevant regulatory approvals.

Building Clinical Confidence and International Partnerships

Participation in both conferences represents a further step in Bioactivx’s international engagement as the company advances its commercialisation efforts.

The interest received provides a foundation for continued discussions with clinicians and potential partners. Bioactivx’s priorities include strengthening clinical evidence, building clinical confidence and establishing partnerships to support entry into additional markets.

Insights gathered in Chile and Los Angeles will also help guide future research as the company works to bring Singapore-developed wound-care technology to a wider patient population.

‍